

Clinical cancer research
v. 17, no. 22 (Nov. 15 2011)
General Collection
W1 CL672
2012-01-04 09:26:07

Clinical Cancer Research

November 15, 2011 • Volume 17 • Number 22 • Pages 6953-7204



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

***The Journal of Clinical and
Translational Research***

Amgen Exhibit 1021
Amgen v. BMS



Accelerating Science:
Concept to Clinic

AACR ANNUAL MEETING 2012

March 31- April 4
McCormick Place West
Chicago, IL



NEW in 2012:

- A revised format for the presentation of accepted clinical trials
- New session series titled Current Concepts and Controversies in Diagnostics, Therapeutics, and Prevention
- New poster session on clinical trials in progress
- A regulatory track with sessions on regulatory science and science policy

Interested in sponsoring a late-breaking or placeholder abstract?

AACR members enjoy the privilege of sponsoring abstracts for AACR Annual Meetings. To sponsor a late-breaking or placeholder abstract, submit your membership application by Wednesday, January 18.

Visit www.aacr.org/benefits to read more about the many benefits of AACR membership.

Early registration deadline:
Thursday, December 22

Late-breaking and placeholder
abstract submission deadline:
Wednesday, January 25

AACR American Association for *Cancer Research*
www.aacr.org/2012meeting

DFA729
11-01-12 13270
207
XL
Group

Deputy Editors

James L. Abbruzzese
Carlos L. Arteaga
Susan E. Bates
John J. Crowley
Jerome Ritz
Eric H. Rubin
Patricia S. Steeg

Senior Editors

Ronald G. Blasberg
James H. Doroshow
Lee M. Ellis
Keith T. Flaherty
Jennifer R. Grandis
William E. Grizzle
Stephen M. Hahn
Thomas C. Hamilton
Roy S. Herbst
Paul Kleihues
Marc Ladanyi
Jonathan Licht
Josep M. Llovet
Owen A. O'Connor
Kenneth Pienta
Alex Sparreboom
Josep Tabernero
Beverly A. Teicher

Statistics in Clinical Cancer Research Section Editors

Michael LeBlanc
J. Jack Lee
Rosemarie Mick
Donna S. Neuberg
Weichung Joe Shih

Editorial Board

Bharat B. Aggarwal
Joseph A. Aisner
Kenneth D. Aldape
Francis Ali-Osman
Carmen J. Allegra
Enrique Alvarez
Rebecca G. Bagley
Frank M. Balis
William E. Barlow
Robert C. Bast, Jr.
David G. Beer
Michael E. Berens
James Berenson
Ray Bergan
Irwin D. Bernstein
Donald A. Berry
Joseph R. Bertino
Kapil N. Bhalla
William Bigbee
Michael J. Birrer
Ernest C. Borden
George J. Bosl
Ruud H. Brakenhoff
Ronald M. Bukowski
Angelika M. Burger
Theresa Busch
Aman U. Buzdar
George A. Calin
Kevin Camphausen
Michael A. Carducci
William E. Carson
Paul B. Chapman
Paul Chiao
Kathleen R. Cho
Fortunato Ciardiello
Gary M. Clark
Robert Clarke
Gary L. Clayman
Ezra E. W. Cohen
Michael B. Cohen
Barbara A. Conley
Kathleen A. Cooney
Jorge E. Cortes
Andrew J. Dannenberg
Albert B. Deisseroth
Robert Diasio
Adam P. Dicker
Catherine Diefenbach
Colin P. Dinney
Robert DiPaola
Ethan Dmitrovsky
Glenn Dranoff
Ronny Drapkin
Louis Dubeau
Raymond N. DuBois
Elizabeth Eklund

Adel K. El-Naggar
Jeffrey Engelman
Francisco J. Esteva
Robert L. Ferris
Soldano Ferrone
William D. Figg
Richard S. Finn
Michelangelo Fiorentino
Antonio T. Fojo
Kenneth A. Foon
David A. Frank
Arthur E. Frankel
Paul Frankel
Ralph S. Freedman
Gary E. Gallick
Varsha V. Gandhi
Stephen L. George
Stanton L. Gerson
Giuseppe Giaccone
Luca Gianni
Bonnie S. Glisson
I. David Goldman
Leo Gordon
James S. Goydos
Steven Grant
Joe W. Gray
Jean L. Grem
Tim F. Greten
Susan Groshen
Anne W. Hamburger
Daniel F. Hayes
Stephen S. Hecht
James G. Herman
Kenneth R. Hess
Fred R. Hirsch
Walter N. Hittelman
Samuel B. Ho
Antje Hoering
Robert M. Hoffman
Shawn E. Holt
Gabriel N. Hortobagyi
Yujin Hoshida
Ralph Hruban
Mien-Chie Hung
John T. Isaacs
Mark A. Israel
Jean-Pierre Issa
Rakesh K. Jain
Pasi Jänne
Jin Jen
Ricky W. Johnstone
Barton A. Kamen
Hagop Kantarjian
Gary Kao
Judith E. Karp
Scott H. Kaufmann

Stanley B. Kaye
Michael J. Kerin
Khandan Keyomarsi
Edward Kim
Timothy J. Kinsella
John M. Kirkwood
Elise C. Kohn
Scott Kopetz
Jason A. Koutcher
Donald Kufe
Rakesh Kumar
Frederick S. Leach
Ho-Young Lee
Jin Soo Lee
Keith Ligon
Stanley Lipkowitz
Paul Liu
Philip O. Livingston
Patricia LoRusso
H. Kim Lyerly
Sami Malek
Sridhar Mani
David A. Mankoff
Li Mao
Maurie Markman
Andrew P. Mazar
David J. McConkey
Ignacio J. Melero
Raymond E. Meyn
Frank Meyskens
Randall E. Millikan
John D. Minna
Bruce D. Minsky
Constantine S. Mitsiades
Michael A. Morse
Hasan Mukhtar
Carolyn Muller
Robert J. Mullin
James L. Mulshine
Byung-Ho Nam
William G. Nelson
Steven J. O'Day
Shuji Ogino
Frank G. Ondrey
Robert Orłowski
Klaus Pantel
Jae-Gahb Park
Harvey I. Pass
Ira Pastan
George Peoples
Roman Perez-Soler
David G. Pfister
Herbert M. Pinedo
Bill Plunkett
Yves Pommier
Pingping Qu

Jerry Radich
Derek Raghavan
Michael Reiss
C. Patrick Reynolds
Andrea Richardson
Paul M. Richardson
Michael J. Robertson
Myrna R. Rosenfeld
Miriam Rosin
Eric K. Rowinsky
Lawrence V. Rubinstein
David P. Ryan
Stefania Scala
Richard Schilsky
Gary K. Schwartz
Michael V. Seiden
Adrian M. Senderowicz
Dennis Sgroi
Jerry W. Shay
Dong M. Shin
Yu Shyr
Edward Silberstein
Richard M. Simon
Shivendra Singh
Susan F. Slovin
Robert J. Solifter
David Solit
Cy A. Stein
Barry Storer
Walter J. Storkus
Chris H. Takimoto
Moshe Talpaz
David Tarin
Joel E. Tepper
Satoshi Teramukai
William D. Travis
Donald L. Trump
David M. Vail
Martine Van Glabbeke
Carter Van Waes
Miguel A. Villalona-Calero
Everett E. Vokes
Robert H. Vonderheide
Michael J. Wargovich
Jeffrey S. Weber
Wolfgang A. Weber
Robert Weil
Louis M. Weiner
Winfried S. Wels
William H. Westra
Theresa L. Whiteside
Ignacio I. Wistuba
Keping Xie
Yun Yen
Benny Chung-Ying Zee

Publishing Information

Clinical Cancer Research

The Journal of Clinical and Translational Research

Print ISSN: 1078-0432 • Online ISSN: 1557-3265

AACR Officers

Judy E. Garber, President
Frank McCormick, President-Elect
Elizabeth H. Blackburn, Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Publications Committee

Michael A. Caligiuri, Chairperson
Christine B. Ambrosone
Andrew J. Barker
Powel H. Brown
Richard M. Caprioli
Arul M. Chinnaiyan
Chi Van Dang
Yves A. De Clerck
Jessica Clague DeHart
Lisa Diller
Levi A. Garraway
F. Peter Guengerich
Ernest T. Hawk
Sandra J. Horning
Nancy E. Hynes
Pasi A. Jänne
Kenneth W. Kinzler
Guillermo Lozano
David R. Parkinson
David Pion-Worms
Christoph Plass
Leona D. Samson
Robert H. Vonderheide
George D. Yancopoulos

Publishing Staff

Publisher
Diane Scott-Lichter

Director, Editorial
Helen Barsky Atkins

Managing Editor
Lori Monteleone

Associate Editor
Jesse Potash

Editorial Staff
Brianna Gallagher
Emily Senerth
William J. Siegmann
Cara E. Vandy

Associate Director, Production
Charlene Skibb

Production Staff
David Livewell
Jeremy Rosenberg
Victoria Salvucci

Director, Electronic Publishing
Michael Beveridge

Electronic Publishing Staff
Shira Carroll
Mary Beth Cunney
Diane M. Marinelli

Associate Director, Sales and Marketing
Nicola L. Hill

Assistant Director, Circulation and Fulfillment
Karola Rac

Marketing and Creative Services

Director
Paul Driscoll

Design Staff
Susan Moore

Clinical Cancer Research [ISSN 1078-0432 (Print), ISSN 1557-3265 (Online)] is published twice a month, one volume per year, by the American Association for Cancer Research, Inc. Periodicals postage paid at Philadelphia, PA, and additional mailing offices. POSTMASTER: Send address changes to *Clinical Cancer Research*, Member Services, AACR, 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106-4404 or E-mail: membership@aacr.org. Copyright 2011 by the American Association for Cancer Research, Inc. Printed on acid free paper in the United States of America.

Submission of Manuscripts

Clinical Cancer Research publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research that bridges the laboratory and the clinic. *Clinical Cancer Research* is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Online submission of new manuscripts is available at <http://ccr.msubmit.net>. Instructions for submitting new manuscripts can be found at www.aacrsmartssubmit.org.

Before submitting a manuscript please refer to the Information for Authors link at <http://clincancerres.aacrjournals.org>.

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$85 per printed page for articles one to six pages in length; \$115 per additional page.

Subscription Information

AACR Members. Subscription options are print with online access or online access only. Contact membership@aacr.org or see <http://www.aacr.org> and go to the membership page for further information.

Institutions and Nonmembers. Contacts listed below are for single-site online access only (limited to one building or library) and optional print subscriptions.

USA, Canada, and Mexico
Turpin Distribution, The Bleachery, 143 West Street, New Milford, CT 06776; phone 860-350-0041, fax 860-350-0039, e-mail turpinna@turpin-distribution.com.

Japan
Send orders and inquiries to one of the following contacts: e-support@maruzen.co.jp; info@jp.swets.com; japan@ebSCO.com; journal@kinokuniya.co.jp; usaco@usaco.co.jp.

Rest of World (excluding above)
Turpin Distribution, Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom; phone +44-0-1767-604-957, fax +44-0-1767-604-957, fax +44-0-1767-601-640, e-mail custserv@turpin-distribution.com.

International subscriptions include cost of surface mail. Expedited mailing is available. Contact Turpin Distribution for rates.

Site Licenses. Send site license (online access open to multiple buildings, locations, remote and proxy) inquiries to sitelicense@aacr.org.

Change of Address. Send change of address notification 60 days in advance and include both old and new addresses. Member subscribers should contact AACR Member Services, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404; e-mail

membership@aacr.org. Nonmember subscribers should contact Turpin Distribution, The Bleachery, 143 West Street, New Milford, CT 06776; e-mail turpinna@turpin-distribution.com, or Turpin Distribution, Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom; e-mail custserv@turpin-distribution.com.

Claims. Claims for missing issues made within 90 days of the issues publication date will be honored while supplies last. Member subscribers should contact membership@aacr.org, phone 215-440-9300, fax 215-440-9412. Institutions and nonmember subscribers should direct claims to Turpin Distribution at the appropriate address above or by e-mail turpinna@turpin-distribution.com.

Single Issue Sales. Single issues and back stock of the journals may be ordered from the AACR main office by calling 866-423-3965 (toll-free) or 215-440-9300. Price of a single issue is \$60 and includes U.S. surface postage. Orders outside of the U.S. are \$65 and include postage.

Advertising Information

Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009 [Phone: (856) 768-9360; Fax: (856) 753-0064].

Copyright and Permissions

As a not-for-profit organization incorporated in the United States, AACR adheres to U.S. copyright law (PL 94-553), which became effective January 1, 1978. The law stipulates that copyright for works is vested in the author from the moment of creation and remains the property of the author until legally transferred. Authors who wish to publish articles and other material in AACR journals must formally transfer copyright to AACR. The copyright transfer form must be signed by all authors before AACR can proceed with publication.

After a manuscript has been deemed potentially acceptable, all authors on the manuscript will be requested to complete an online copyright transfer agreement through the SmartSubmit system. If an author is unable to complete the copyright transfer agreement online, the form can be downloaded at <http://www.aacr.org/home/scientists/publications-of-the-aacr/copyright-permissions.aspx> and can be returned to the e-mail address or fax number noted on the form. The AACR journals will not publish a paper unless forms have been properly completed and returned by ALL authors.

To read the complete version of AACR's Copyright and Permissions Policy, please visit <http://www.aacrjournals.org/misc/fora.shtml#copyrightpermissions>. This policy includes further information on authors' rights of usage, permission requests from third parties, free access to AACR journals, funding agency requirements, and the National Institutes of Health Public Access Policy. *Clinical Cancer Research* is abstracted and/or indexed in Chemical Abstracts, Current Contents/Clinical Medicine, Index Medicus, and MEDLINE.

No responsibility is accepted by the Editors or by AACR, Inc. for the opinions expressed by contributors or for the content of the advertisements.

American Association for Cancer Research
615 Chestnut Street
Philadelphia, PA 19106-4404
Phone: 215-440-9300
Fax: 215-440-9354
E-mail: ccr@aacr.org
Website: www.aacr.org

Highlights of This Issue 6953

SPECIAL FEATURES

CCR Translations

- 6955 | **MAGE: The Spell Is Broken**
Katayoun Rezvani
See article p. 7058

CCR Drug Updates

- 6958 | **Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma**
Evan J. Lipson and Charles G. Drake

Molecular Pathways

- 6963 | **Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells**
Nicola Giuliani and Irma Airolidi

Perspective

- 6971 | **DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies**
Graham A. Colditz and John Crowley

Reviews

- 6973 | **DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target**
Shadia Jalal, Jennifer N. Earley, and John J. Turchi
- 6985 | **Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives**
Jessica Godin-Ethier, Laïla-Aïcha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

HUMAN CANCER BIOLOGY

- 6992 | **Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I**
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsvankin, Marci Klaassen, B.K. Kleinschmidt-DeMasters, and Allen Waziri
- 7003 | **Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB-NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome**
Yoshitsugu Mitani, Pulivarthi H. Rao, P. Andrew Futreal, Dianna B. Roberts, Philip J. Stephens, Yi-Jue Zhao, Li Zhang, Mutsumi Mitani, Randal S. Weber, Scott M. Lippman, Carlos Cautin, and Adel K. El-Naggar
- 7015 | **Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma**
David Z. Chang, Ying Ma, Baoan Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yong-jun Liu, Craig D. Logsdon, and Patrick Hwu
- 7024 | **Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis**
Aditi Bhattacharya, Ritu Roy, Antoine M. Snijders, Gregory Hamilton, Jesse Paquette, Taku Tokuyasu, Henrik Bengtsson, Richard C. K. Jordan, Adam B. Olshen, Daniel Pinkel, Brian L. Schmidt, and Donna G. Albertson
- 7035 | **Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium**
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu

CANCER THERAPY: PRECLINICAL

- 7047 **Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy**
Yuhuan Li, Li-Xin Wang, Puiyi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu
- 7058 **Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4**
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard
See commentary p. 6955
- 7067 **Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells**
Andreas Höglund, Lisa M. Nilsson, Somsundar Veppil Muralidharan, Lisa A. Hasvold, Philip Merta, Martina Rudelius, Viktoriya Nikolova, Ulrich Keller, and Jonas A. Nilsson
- 7080 **Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies**
Hwa Jin Lee, Brian A. Wall, Janet Wangari-Talbot, Seung-Shick Shin, Stephen Rosenberg, Joseph L-K. Chan, Jin Namkoong, James S. Goydos, and Suzie Chen
- 7093 **Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma**
Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Maldonado, Yves A. DeClerck, and C. Patrick Reynolds
- 7105 **Reduced miR-128 in Breast Tumor-Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5**
Yinghua Zhu, Fengyan Yu, Yu Jiao, Juan Feng, Wei Tang, Herui Yao, Chang Gong, Jianing Chen, Fengxi Su, Yan Zhang, and Erwei Song
- 7116 **Novel Phosphoinositide 3-kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells *In Vitro* and *In Vivo***
Kwang-Yu Chang, Shan-Yin Tsai, Ching-Ming Wu, Chia-Jui Yen, Bin-Fay Chuang, and Jang-Yang Chang

7127

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Koblish, Leslie M. Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jincong Zhuo, Wenqing Yao, Robert C. Newton, and Peggy A. Scherle

IMAGING, DIAGNOSIS, PROGNOSIS

7139

Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival

Anna E. Coghil, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutter, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

7148

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larisa Lapre, Pieter Wesseling, Johannes L. Teepe, Ahmed Idhah, Marc Sanson, Peter A.E. Sillevs Smitt, and Pim J. French

CANCER THERAPY: CLINICAL

7156

Biologic and Clinical Activity of Tivozanib (AV-951, KR-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

7164

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacquie Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlom, and James L. Gulley

GLIPRI Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohei Edamura, Ken-ichi Tabata, Chengzhen Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

Relationship between Quantitative *GRB7* RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Joseph A. Sparano, Lori J. Goldstein, Barrett H. Childs, Steven Shak, Diana Brassard, Sunil Badve, Frederick L. Baehner, Roberto Bugarini, Steve Rowley, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson, Paraic A. Kenny, George W. Sledge, Jr, and Robert Gray


PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.



Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

Evan J. Lipson and Charles G. Drake

Abstract

Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group (hazard ratio, 0.68; $P \leq 0.003$). Serious (grade 3–5) immune-related adverse events occurred in 10% to 15% of patients. Thus, although it provides a clear survival benefit, ipilimumab administration requires careful patient monitoring and sometimes necessitates treatment with immune-suppressive therapy. Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma. *Clin Cancer Res*; 17(22); 6958–62. ©2011 AACR.

Introduction

T cells, both CD4 (helper) and CD8 (cytotoxic), contribute to the adaptive immune response against pathogens and tumors, and activation and recruitment of specific T cells constitute a complex process. For a T cell to become fully activated (and subsequently proliferate and mediate effector function), at least 2 receptor–ligand interactions are required. The first of these occurs when the unique receptor of the T cell recognizes its cognate ligand, a short peptide presented in the context of a MHC molecule. This interaction is exquisitely specific, and if a good fit occurs, T-cell activation is initiated. However, full activation of a CD4 or CD8 T cell requires a second signal transmitted by costimulatory molecules present on the same antigen-presenting cell that expresses the peptide/MHC. This second signal is transmitted from costimulatory molecules (B7.1 and/or B7.2) to a receptor on T cells known as CD28. Only when both signals are received and integrated does a specific T cell proliferate, acquire effector function, and migrate to sites of antigen expression.

CTL antigen 4 (CTLA-4) was first cloned in 1987 (1). Subsequent studies showed this molecule to be a homolog

of CD28, suggesting that CTLA-4 might serve, along with CD28, as a costimulatory molecule (2). However, several other studies provided opposing results, and for some time, it was not clear whether CTLA-4 transmitted a stimulatory or inhibitory signal to T cells. The generation of mice lacking CTLA-4 provided a solution for this conundrum: Knockout mice developed a progressive accumulation of activated T cells and died of lymphoproliferative disease ~3 to 4 weeks after birth (3). These and other results (4) suggested that blockade of CTLA-4 with a monoclonal antibody could augment an adaptive immune response to an infectious agent or an evolving tumor. The seminal study in this area (5) showed that CTLA-4 blockade could attenuate the growth of several implanted murine tumors, consistent with the model shown in Fig. 1. On an immunologic basis, this model of T-cell activation and the function of CTLA-4 represents a significant simplification. A more complete description can be found in several relevant reviews (6, 7).

Early Clinical Development

To translate these findings into a clinical setting, the Medarex Corporation generated a series of monoclonal antibodies using a unique transgenic mouse (HuMAb), in which the endogenous murine immunoglobulin genes have been knocked out and replaced with human loci (8). Immunization of these mice results in fully human monoclonal antibodies devoid of murine sequences that can lead to infusion reactions. The clinical development of MDX-010 was recently reviewed (8); only several selected trials that are most relevant in terms of the current U.S. Food and Drug Administration (FDA) approval for use in melanoma will be outlined here.

Authors' Affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Corresponding Author: Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB, Room 410, Baltimore, MD 21231. Phone: 410-502-7523; Fax: 443-287-4653; E-mail: cdrake@jhmi.edu

doi: 10.1158/1078-0432.CCR-11-1595

©2011 American Association for Cancer Research.




Figure 1. A, melanoma cells express proteins, such as gp100, MART-1, and tyrosinase, that may be processed and presented by antigen-presenting cells. T-cell recognition of peptide antigens derived from these proteins can potentially drive an antitumor immune response. For such tumor-directed T cells to become activated, 2 signals are required. The first signal (signal 1) occurs when the peptide antigen is recognized by the T-cell receptor on antigen-specific T cells. This recognition is exquisitely specific. However, for full T-cell activation, proliferation, and effector function, a second signal (signal 2) is needed. This signal is typically mediated by the interaction between costimulatory molecules such as B7.1 and B7.2 on antigen-presenting cells and CD28 on T cells. In reality, the situation is more complex, and signal 2 is derived from the integration of several positive and negative events. B, under certain conditions, T cells upregulate the cell surface molecule CTLA-4, which binds to B7.1 and B7.2 with greater affinity than does CD28. This series of events effectively hijacks signal 2, resulting in a situation in which specific T cells cannot be fully activated. C, ipilimumab (and other anti-CTLA-4 antibodies) bind to CTLA-4 on the cell surface, effectively blocking the interaction between CTLA-4 and B7.1/B7.2. This leads to interruption of the negative signal mediated by CTLA-4, the resumption of signal 2, and a relative restoration of T-cell activation.

Initial phase I studies included both single and repetitive dosing regimens and showed safety and an intriguing suggestion of efficacy (8). In subsequent trials at the National Cancer Institute, investigators administered ipilimumab, first at 3 mg/kg along with a gp100 multi-peptide vaccine, and then at doses between 1 and 3 mg/kg (9, 10). They observed sustained responses (>2 years) in several patients. Immune-related adverse events (irAE) were also seen and seemed to correlate with clinical response. An important phase I/II study to determine the pharmacokinetic profile of MDX-010 was conducted in patients with metastatic melanoma (11). A secondary endpoint of this study (MDX-015) was clinical activity, and the study included both single- and multiple-dosing regimens. Escalating single doses of up to 20 mg/kg, as well as every-3-weeks dosing at 10 mg/kg, were examined. Although the study was not adequately powered to compare regimens, the group of patients who received 10 mg/kg every 3 weeks had the highest disease control rate. This study also confirmed the toxicity profile noted in earlier trials, with 19% of patients experiencing grade 3 or 4 adverse events. Many of these events were irAEs, predominantly colitis, rash, and liver function abnormalities. In this study, irAEs appeared to be somewhat correlated with response and were observed in 13 of 14 patients with stable disease, as well as in all 4 patients with an objective response.

Based partially on these findings, a randomized, multi-institution, double-blind, dose-ranging study was performed (12). This study (CA184-022) enrolled 217 patients with previously treated metastatic melanoma, and the patients were randomized to doses of 0.3, 3, or 10 mg/kg MDX-010 administered every 3 weeks. Patients without progressive disease at week 24 entered into a maintenance phase in which MDX-010 continued to be administered every 12 weeks. The primary endpoint of this study was efficacy. The best overall response rates were 0%, 4.2%, and 11.1% in the 0.3-mg/kg, 3-mg/kg, and 10-mg/kg groups, respectively. Survival data were encouraging, with 30% of patients in the 10-mg/kg cohort alive at 2 years, as opposed to 18% in the 0.3-mg/kg cohort. IrAEs were again noted in 0%, 5%, and 18% of patients in the 3 dose cohorts. These findings supported the efficacy of MDX-010 and reinforced the every-3-weeks dosing regimen that was subsequently adapted for phase III investigation.

In terms of combination studies, the safety and efficacy of ipilimumab administered with dacarbazine was first investigated in a phase II trial that randomized 72 chemotherapy-naïve patients to receive ipilimumab at 3 mg/kg every 4 weeks for 4 doses either alone or with dacarbazine (13). The primary endpoint, the objective response rate, was 14.3% [95% confidence interval (CI), 4.8–30.3] with ipilimumab plus dacarbazine and 5.4% (95% CI, 0.7–18.2) with ipilimumab alone; that is, there was a trend toward an increased response rate in the combination treatment group.

Late-Stage Development

Positive results from a pivotal phase III trial of MDX-010 were reported in 2010 (14). This study randomized 676

HLA-A*0201-positive, previously treated melanoma patients 1:3:1 to ipilimumab alone, ipilimumab plus a gp100 vaccine, or gp100 vaccine alone. Mirroring the phase II schedule, ipilimumab was administered every 3 weeks for up to 4 doses at 3 mg/kg. The primary endpoint of this study, overall survival, was significantly better in the groups receiving ipilimumab than in the group receiving gp100 vaccine alone: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group [hazard ratio (HR), 0.68; $P \leq 0.003$]. The best overall response rate was 10.9% in the ipilimumab-alone cohort, compared with 5.7% in the ipilimumab plus vaccine group and 1.5% for vaccine alone. The longitudinal survival benefit suggested by phase II studies was confirmed, with 22% of ipilimumab-alone patients alive at 24 months, versus 24% for ipilimumab plus vaccine and 14% for vaccine alone. The rate of grade 3/4 irAEs was also comparable with that observed in previous studies: 10% to 15% in the ipilimumab groups compared with 3% in the gp100 group. This study was especially significant in that it was the first randomized study ever to show a survival benefit in patients with metastatic melanoma.

Similar positive results were seen when ipilimumab was administered as first-line therapy (15). In a randomized phase III study, 502 patients with previously untreated metastatic melanoma were randomized 1:1 to ipilimumab (10 mg/kg) plus dacarbazine (850 mg/m²) or dacarbazine plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with an objective response or stable disease and no dose-limiting adverse effects received maintenance ipilimumab or placebo every 12 weeks thereafter. Overall survival (the primary endpoint of the trial) at 1 year in the ipilimumab–dacarbazine group was 47%, compared with 36% in the dacarbazine–placebo group. Grade 3/4 adverse events were noted more frequently than in trials not involving chemotherapy (56% ipilimumab plus dacarbazine, 28% dacarbazine plus placebo). Of interest, the pattern of irAEs was different, with more frequent hepatotoxicity (~20%) and less frequent colitis (2%). Overall, this study played an important role in bringing ipilimumab into the first-line setting for metastatic melanoma and in showing that the patterns of toxicity of this agent can vary depending on the context in which it is administered. It should be noted that although this study provided information about the safety and tolerability of ipilimumab dosed at 10 mg/kg, the FDA approved the drug at a dosage of 3 mg/kg.

Integration of Ipilimumab into the Melanoma Treatment Paradigm

Currently, few therapeutic options are available for patients with unresectable American Joint Committee on Cancer stage III or stage IV melanoma. Chemotherapy regimens include paclitaxel alone or with a platinum agent,

temozolomide, or dacarbazine. Immune therapies include dacarbazine- or temozolomide-based biochemotherapy and high-dose interleukin-2 (IL-2), which result in clinical responses in ~15% to 20% of patients, about one third of whom experience durable, complete responses (16, 17). Administration of IL-2, however, is limited to patients with an excellent performance status who have no evidence of cardiac dysfunction or active central nervous system metastases. Given these constraints, the addition of ipilimumab to the therapeutic armamentarium is particularly welcome because it expands the population of patients who can receive immunotherapy. Indeed, the National Comprehensive Cancer Network (NCCN) has added ipilimumab as a category 1 recommendation in its guidelines of systemic therapy options for advanced or metastatic melanoma (18).

In clinical practice, the order in which a patient receives different therapies may become relevant, particularly if irAEs are encountered. Although high-dose IL-2 administration may be complicated by side effects around the time of drug delivery, such side effects will generally resolve completely within several weeks. The same is not true with certain of the irAEs seen with ipilimumab (19). Some patients who develop ipilimumab-related pan-hypopituitarism, for example, will require long-term replacement with multiple steroid hormones, potentially disqualifying them from receiving IL-2. It may make sense, then, for patients who could tolerate either IL-2 or ipilimumab as initial therapy to consider beginning treatment with IL-2.

The irAEs associated with ipilimumab treatment (Table 1) necessitate careful patient selection as well as thorough and frequent patient monitoring. The NCCN guidelines note "Ipilimumab should be used with extreme caution, if at all, in patients with serious underlying autoimmune disorders." Bristol-Myers Squibb, in collaboration with the FDA, has developed a Risk Evaluation and Mitigation Strategy program designed to facilitate early identification and appropriate management of patients with moderate or severe irAEs. In addition, comprehensive toxicity management algorithms have been developed and are included in the ipilimumab package insert. It is important to note that the vast majority of these irAEs are reversible with early intervention. Moreover, it appears that the majority of antitumor responses persist despite corticosteroid therapy (11).

A further unresolved question involves the concept of ipilimumab maintenance therapy. It should be noted that in the ipilimumab plus dacarbazine trial, patients who had stable disease or an objective response and no dose-limiting toxic effects after receiving 4 doses of ipilimumab (10 mg/kg) at weeks 1, 4, 7, and 10 received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. This treatment was administered until disease progression or development of toxicities occurred, or until conclusion of the study. This design was similar to that used in the aforementioned phase II trial CA184-022. Likewise, Hodi and colleagues (14) offered additional courses of a participant's assigned treatment (reinduction) to patients with stable disease of 3 months' duration after week 12 or a

Table 1. Presentation of immune-related adverse events

Area affected	Symptoms at presentation
Gastrointestinal system	Diarrhea, abdominal pain, blood in stools, increased frequency of stools, nausea, vomiting, or constipation, with or without fever; complications may include intense bleeding, bowel perforations, intense diarrhea, or need for colectomy
Skin	Rash, usually maculopapular and often accompanied by significant generalized pruritus
Liver	Right upper quadrant abdominal pain, nausea, vomiting, elevated aspartate aminotransferase/alanine aminotransferase, or hyperbilirubinemia in the absence of clinical symptoms
Nervous system	Muscle weakness or sensory neuropathies, Guillain-Barré syndrome
Endocrine system	Nonspecific symptoms, including headache, visual-field defects, behavioral changes, decreased libido, fatigue, new onset of atrial fibrillation, weakness, asthenia, anorexia, nausea and vomiting, lethargy, impotence, amenorrhea, fever, coma, hypotension, hypoglycemia, hyponatremia, and eosinophilia

confirmed partial or complete response. In that study, ipilimumab was dosed at 3 mg/kg. FDA approval for ipilimumab does not include maintenance dosing. Although maintenance or reinduction therapy was included in the above studies and both approaches are currently being examined in several nonmelanoma trials (e.g., CA184-043 and CA184-095 for prostate cancer), the role of these therapies is still unclear.

Future Directions

In addition to its documented activity in metastatic melanoma, ipilimumab has shown early evidence of clinical activity in several additional tumor types, including renal cell, lung, and prostate cancers. Two ongoing randomized phase III studies are evaluating ipilimumab in patients with metastatic castrate-resistant prostate cancer either before (CA184-095) or after (CA184-043) administration of docetaxel. In addition, phase II studies combining ipilimumab with standard chemotherapy or other immunotherapy modalities are ongoing in a number of tumor types (NCT01331525, NCT01194271).

Combining ipilimumab with targeted therapy, such as the BRAF inhibitor vemurafenib, will almost certainly become an area of active investigation in the near future. A recent report by Chapman and colleagues (20) showed improved survival for patients with stage IV melanoma treated with vemurafenib compared with standard chemotherapy with dacarbazine. At 6 months, overall survival was 84% in the vemurafenib group and 64% in the dacarbazine group. Vemurafenib has a remarkably high response rate (48% for vemurafenib vs. 5% for dacarbazine) in patients with V600E mutated melanoma, and thus it may be well suited to decrease or mitigate a tolerogenic tumor burden. Additionally, *in vitro* data suggesting that vemurafenib does not lead to decreased adaptive immunity (21) lend further support to the upcoming trial of vemurafenib plus ipilimumab for patients with BRAF mutation-positive melanoma (NCT01400451).

Another interesting issue regarding the future development of ipilimumab involves its combination with cancer vaccines. Indeed, many of the preclinical studies of this agent showed remarkable enhancement of activity when it was combined with anticancer vaccines, particularly cell-based vaccines that secrete granulocyte macrophage colony-stimulating factor. Some of the earliest published data in this regard showed that the combination of anti-CTLA-4 plus GVAX was able to cure established, poorly immunogenic B16 melanomas, a result that was not achievable with either agent alone (22). However, these results were not reflected in the pivotal phase III trial discussed above (14). This apparent discrepancy most likely stems from the nature of the gp100 vaccine used (2 epitopes administered s.c. in incomplete Freund's adjuvant). Comparative data supporting the clinical efficacy of this particular gp100 vaccine were not striking. In a randomized phase III trial, in combination with IL-2, the vaccine showed a small but statistically significant improvement in progression-free survival (2.2 vs. 1.6 months) but no significant improvement in overall survival (23). It is critically important to note that negative data derived from one particular vaccine should not be misinterpreted as evidence that other ipilimumab/vaccine combinations could not confer additive or synergistic efficacy.

With the best overall response rates in the 10% to 15% range in most published studies, it appears that ipilimumab is not effective in the vast majority of patients treated. In addition, the significant rate of irAEs and other adverse events compels the development and prospective validation of a predictive biomarker that would allow pretreatment selection of patients likely to benefit from treatment. Unfortunately, no such marker appears imminent, despite the ~3,500 patients treated with this agent to date (8). Some insight in this area was provided by the recent observation that patients with an absolute lymphocyte count $\geq 1,000/\mu\text{L}$ after 2 ipilimumab treatments had a significantly improved clinical benefit rate and median overall survival compared with patients with a count of $<1,000/\mu\text{L}$ (24). Future studies, perhaps involving paired tumor biopsy analysis or

serum antibody profiling, are clearly needed to identify those patients whose disease is most likely to respond to ipilimumab.

Conclusions

The development and FDA approval of ipilimumab represent a major step forward in cancer immunotherapy. Although multiple phase III trials have confirmed a survival benefit for this agent, perhaps the most compelling data are those showing a small but significant proportion of patients with metastatic melanoma surviving 2 and even 3 years from the time of treatment initiation. Given the significant rate of irAEs, clinical application of ipilimumab is challenging and requires careful monitoring and prompt attention to potential adverse events. Future clinical research will likely address the development and verification of predictive biomarkers, permitting the identification of a subgroup of patients most likely to derive clinical benefit. Perhaps more exciting, though, is the

potential for additive and/or synergistic efficacy, which may be achieved by combining ipilimumab with targeted agents such as vemurafenib, with radiotherapy, or perhaps with cancer vaccines that optimally prime a tumor-specific T-cell response.

Disclosure of Potential Conflicts of Interest

C.G. Drake is a clinical investigator for Damon Runyon-Lilly; serves as a consultant for Dendreon and Pfizer; has served as a paid consultant for Bristol-Myers Squibb and, through Johns Hopkins University, has licensed patents to that entity; and has an ownership interest in Amplimmune and Bristol-Myers Squibb. E.J. Lipson disclosed no potential conflicts of interest.

Grant Support

NIH (R01 CA127153 and 1P50CA58236-15), Patrick C. Walsh Fund, OneInSix Foundation, and Prostate Cancer Foundation. E.J. Lipson was supported by the John P. Hussman Foundation and an NIH/NCI T32 training grant.

Received June 22, 2011; revised August 4, 2011; accepted August 7, 2011; published OnlineFirst September 7, 2011.

References

- Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily—CTLA-4. *Nature* 1987;328:267–70.
- Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. *Immunity* 1997;7:445–50.
- Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. *Science* 1995;270:985–8.
- Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 1995;3:541–7.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 1996;271:1734–6.
- Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. *Immunol Rev* 2008;224:141–65.
- Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. *Immunol Rev* 2011;241:180–205.
- Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. *Semin Oncol* 2010;37:533–46.
- Attia P, Phan GQ, Maker AV, Robinson MR, Quezada MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. *J Clin Oncol* 2005;23:6043–53.
- Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* 2003;100:8372–7.
- Weber JS, O'Day S, Urban W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. *J Clin Oncol* 2008;26:5950–6.
- Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol* 2010;11:155–64.
- Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. *Invest New Drugs* 2011;29:489–98.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–23.
- Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517–26.
- Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000;6[Suppl 1]:S11–4.
- Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. *Ann Surg* 1998;228:307–19.
- National Comprehensive Cancer Network. [Cited 2011 Oct 21] Available from: http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf.
- Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. *Cancer Immunol Immunother* 2009;58:823–30.
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507–16.
- Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jallil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. *Clin Cancer Res* 2010;16:6040–8.
- van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J Exp Med* 1999;190:355–66.
- Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med* 2011;364:2119–27.
- Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. *Cancer* 2010;116:1767–75.